Physician profile
Jose E Piovanetti
NPI 1851382881
$3,594.29
in general payments reported to CMS, 2019-2025
28 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.28 · 2020: $453 · 2021: $827 · 2022: $1,079 · 2023: $616 · 2024: $349 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.47 | 2021-2025 | |
| Pfizer INC. | $450.55 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $273.35 | 2021-2023 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $271.64 | 2021-2025 | |
| Alkermes, INC. | $207.93 | 2021-2024 | Lybalvi |
| Allergan, INC. | $189.01 | 2019-2020 | |
| Novo Nordisk INC | $180.28 | 2021-2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $154.06 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $146.24 | 2020-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $138.27 | 2020-2022 | |
| Amarin Pharma, INC. | $131.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $109.79 | 2023-2024 | Farxiga, Lokelma, Airsupra |
| Supernus Pharmaceuticals, INC. | $109.73 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $105.82 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.75 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $80.06 | 2021-2022 | |
| Orexo US, INC. | $68.13 | 2019-2022 | |
| Indivior INC. | $46.84 | 2019-2023 | Sublocade |
| Noven Therapeutics, LLC | $37.21 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $36.01 | 2024-2025 | |
| Almatica Pharma LLC | $32.16 | 2021-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $31.63 | 2025 | Cobenfy |
| Exact Sciences Corporation | $23.34 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2024 | Jardiance |
| Axsome Therapeutics, INC. | $17.90 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $14.48 | 2021 | |
| Eisai INC. | $13.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Piovanetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.